BCL2 and acute myeloid leukemia: The targeting of apoptosis-related genes has so far generally failed to advance to the clinical setting as expected and remains aspirational but encouraged by the recent FDA approval of the Bcl-2-specific inhibitor venetoclax for the treatment of chronic lymphatic leukemia (CLL) and acute myeloid leukemia (AML) [153].